Home > Dermatology > EADV 2022 > Vitiligo in 2022 > Enhancing re-pigmentation rates with topical ruxolitinib in all body areas

Enhancing re-pigmentation rates with topical ruxolitinib in all body areas

Presented by
Prof. Thierry Passeron, University Côte d’Azur, France
Conference
EADV 2022
Trial
Phase 3, TRuE-V1; TRuE-V2
Doi
https://doi.org/10.55788/5f18f06c
Evaluating phase 3 data of JAK inhibition with ruxolitinib according to different regions of the body demonstrated the best results for head and neck with 68.1% of patients reaching >50% repigmentation after 1 year. Of note, also very difficult-to-treat areas like hands and feet responded very well to the treatment.

Within the TRuE-V1 (NCT04052425) and TRuE-V2 (NCT04057573) trials, ruxolitinib cream demonstrated superior efficacy over placebo at week 24, not only in the primary but also all secondary endpoints [1,2]. “We know that the location is very important when it comes to re-pigmentation of vitiligo, and we know that extremities are much more difficult, but also some other areas on the body,” Prof. Thierry Passeron (University Côte d’Azur, France) expressed as the underlying reason for an analysis of the data according to efficacy in different body regions [1]. The studies included vitiligo patients ≥12 years of age with ≤10% of depigmented body surface area of which at least 0.5% had to be facial and ≥3% in other body sites. For the new evaluation, endpoints were ≥50% improvement in the Vitiligo Area Scoring Index (VASI50) Score at week 24 in: head and neck, hands, upper/lower extremities, trunk including genitals, feet, as well as total body with exclusion of the face.

In TRuE-V1 and V2, participants were randomised to twice daily 1.5% ruxolitinib cream or placebo until week 24, whereafter all participants continued on the study drug to week 52. At 6 months, the results were in favour of the ruxolitinib cream as compared with placebo, regardless of the body region. Best results for ruxolitinib versus placebo at week 24 were noted in head and neck (45.3% vs 23.8%), followed by the extremities (arms 33.2% vs 8.2%, legs 29.5% vs 12.2%). Prof. Passeron highlighted that even hands and feet, 2 very resistant areas to treat, provided good results. As re-pigmentation treatment in vitiligo takes time, the results of the ruxolitinib groups further improved up to week 52: VASI50 was reached for total body without the facial area in 47.7%, head and neck 68.1%, upper extremities 56.7%, lower extremities 54.5%, trunk 48.4%, hands 38.2%, and feet 29.3%. In comparison, the respective rates for reaching VASI50 in former placebo patients changing to ruxolitinib at week 24 were: 23.3%, 51.0%, 34.9%, 32.3%, 25.4%, 29.2%, and 22.5%. “Not surprisingly, hands and feet that are the most difficult parts to re-pigment, but you can see that even so about one third of the patients reach 50% of re-pigmentation after 1 year of treatment,” Prof. Passeron underlined. Interestingly, the increase of patients reaching VASI50 over time did not plateau after 1 year.

“This subanalysis demonstrated that after 6 months and after 1 year, ruxolitinib cream provided not only good results on the face but also on other parts of the body, which is very important for the patients,” Prof. Passeron summarised, reminding the audience that it is important to explain to the patients that treatment will go on for a long time.

  1. Passeron T. Effect of Ruxolitinib Cream on Achievement of VASI50 by Body Region: Week 52 Pooled Analysis of the TRuE-V Phase 3 Studies. 1C, EADV Congress 2022, Milan, Italy, 7‒10 September.
  2. Rosmarin D. Efficacy and safety of ruxolitinib cream monotherapy for the treatment of vitiligo: results from 2 52-week phase 3 studies. S026, AAD 2022 Annual Meeting, Boston, MA, USA, 25–29 March.

Copyright ©2022 Medicom Medical Publishers



Posted on